Trial Profile

Phase I Study of MK-3475 in Combination With BCG for Patients With High Risk Superficial Bladder Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bladder cancer vaccine (Primary) ; Pembrolizumab (Primary)
Indications Bladder cancer
Focus Adverse reactions
Acronyms MARC

Most Recent Events

02 Sep 2024 Status changed from active, no longer recruiting to completed.
07 Jun 2022 Results assessing international prostate symptom score for intravesical bacillus Calmette-Guerin in patients high-grade non-muscle-invasive bladder cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology
16 May 2022 Results of two year efficacy follow up of phase 1 trial presented at the 117th Annual Meeting of the American Urological Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com